Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound.
Focal therapy
High-intensity focused ultrasound
Magnetic resonance imaging
Prostate cancer
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
25
5
2020
medline:
22
6
2021
entrez:
25
5
2020
Statut:
ppublish
Résumé
For clinically significant, locally confined prostate cancer, whole-gland radical prostatectomy and radiotherapy are established effective treatment strategies that, however, come at a cost of significant morbidity related to urinary and sexual side effects. The concept of risk stratification paired with a better understanding of prognostic factors has led to the development of alternative management options including active surveillance and focal therapy for appropriately selected patients with localized disease. High-intensity focused ultrasound (HIFU) is one such minimally invasive, image-guided treatment option for prostate cancer. Due to the relative novelty of HIFU and the increased use of magnetic resonance imaging in prostate cancer, many radiologists are not yet familiar with imaging findings related to HIFU, their temporal evolution as well as imaging appearance of recurrent disease after this type of focal therapy. HIFU induces sharply demarcated, localized coagulative necrosis of a tumor through thermal energy delivered via an endorectal or transurethral ultrasound transducer. In this pictorial review, we aim at providing relevant background information that will guide the reader through the general principles of HIFU in the prostate, as well as demonstrate the imaging appearance of expected post-HIFU changes versus recurrent tumor.
Identifiants
pubmed: 32447414
doi: 10.1007/s00261-020-02577-5
pii: 10.1007/s00261-020-02577-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3882-3895Références
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117 (13):2883-2891. https://doi.org/10.1002/cncr.25900
doi: 10.1002/cncr.25900
pubmed: 21692049
pmcid: 3139725
Bianco FJ, Scardino PT, Eastham JA (2005) Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66 (5, Supplement):83-94. https://doi.org/10.1016/j.urology.2005.06.116
Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A (2012) Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 82 (1):204-212. https://doi.org/10.1016/j.ijrobp.2010.10.009
doi: 10.1016/j.ijrobp.2010.10.009
pubmed: 21167653
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. European Urology 63 (4):597-603. https://doi.org/10.1016/j.eururo.2012.11.005
doi: 10.1016/j.eururo.2012.11.005
pubmed: 23159452
Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA (2019) Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol 31 (3):200-206. https://doi.org/10.1097/CCO.0000000000000515
doi: 10.1097/CCO.0000000000000515
pubmed: 30865133
pmcid: 6465079
Hectors SJCG, Jacobs I, Moonen CTW, Strijkers GJ, Nicolay K (2016) MRI methods for the evaluation of high intensity focused ultrasound tumor treatment: Current status and future needs. Magnetic Resonance in Medicine 75 (1):302-317. https://doi.org/10.1002/mrm.25758
doi: 10.1002/mrm.25758
pubmed: 26096859
Barkin J (2011) High intensity focused ultrasound (HIFU). Can J Urol 18 (2):5634-5643
pubmed: 21504653
Ishihara Y, Calderon A, Watanabe H, Okamoto K, Suzuki Y, Kuroda K, Suzuki Y (1995) A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med 34 (6):814-823. https://doi.org/10.1002/mrm.1910340606
doi: 10.1002/mrm.1910340606
pubmed: 8598808
Kirkham APS, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C (2008) MR Imaging of Prostate after Treatment with High-Intensity Focused Ultrasound. Radiology 246 (3):833-844. https://doi.org/10.1148/radiol.2463062080
doi: 10.1148/radiol.2463062080
pubmed: 18223121
Apfelbeck M, Clevert DA, Ricke J, Stief C, Schlenker B (2018) Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. Clin Hemorheol Microcirc 69 (1-2):93-100. https://doi.org/10.3233/ch-189123
doi: 10.3233/ch-189123
pubmed: 29660918
Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E, Ezziane M, de Guibert PJ, Tavolaro S, Belin L, Boudghene F, Lucidarme O, Renard-Penna R (2018) Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed? Eur Radiol 28 (9):3760-3769. https://doi.org/10.1007/s00330-018-5352-z
doi: 10.1007/s00330-018-5352-z
pubmed: 29633004
Hötker AM, Meier A, Mazaheri Y, Zheng J, Capanu M, Chaim J, Sosa R, Coleman J, Hricak H, Akin O (2019) Temporal changes in MRI appearance of the prostate after focal ablation. Abdom Radiol (NY) 44 (1):272-278. https://doi.org/10.1007/s00261-018-1715-9
doi: 10.1007/s00261-018-1715-9
Berge V, Dickinson L, McCartan N, Hindley RG, Diep LM, Emberton M, Ahmed HU (2014) Morbidity Associated with Primary High Intensity Focused Ultrasound and Redo High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology 191 (6):1764-1769. https://doi.org/10.1016/j.juro.2013.12.036
doi: 10.1016/j.juro.2013.12.036
Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Shah K, van der Meulen J, Virdi J, Winkler M, Emberton M, Ahmed HU (2018) A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 74 (4):422-429. https://doi.org/10.1016/j.eururo.2018.06.006
doi: 10.1016/j.eururo.2018.06.006
pubmed: 29960750
pmcid: 6156573
Rigo M, Mazzola R, Napoli G, Giaj-Levra N, Figlia V, Nicosia L, Ricchetti F, Tomasini D, Bonu ML, Cuccia F, Bellorofonte C, Alongi F (2020) Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiol Med. https://doi.org/10.1007/s11547-020-01148-4
doi: 10.1007/s11547-020-01148-4
pubmed: 32077006
Finelli A, Van der Kwast T, Ryan P, Bolton D, Fleshner N, Trachtenberg J, Klotz L, Robinette M, Woo H (2011) Salvage Radical Prostatectomy Following Primary High Intensity Focused Ultrasound for Treatment of Prostate Cancer. The Journal of urology 185:862-868. https://doi.org/10.1016/j.juro.2010.10.080
doi: 10.1016/j.juro.2010.10.080
pubmed: 21239003
Peretsman S, Brooks J (2017) Salvage robotic prostatectomy following whole gland high-intensity focused ultrasound with a Sonablate 500 device: technical feasibility and safety. J Robot Surg 11 (2):217-221. https://doi.org/10.1007/s11701-016-0649-x
doi: 10.1007/s11701-016-0649-x
pubmed: 27995543
Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2018) Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol 199 (4):990-997. https://doi.org/10.1016/j.juro.2018.01.002
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 71 (4):618-629. https://doi.org/10.1016/j.eururo.2016.08.003
Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward JF (2017) Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int 119 (6):896-904. https://doi.org/10.1111/bju.13766
doi: 10.1111/bju.13766
pubmed: 28063191
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M (2014) Prostate Cancer, Version 2.2014. 12 (5):686. https://doi.org/10.6004/jnccn.2014.0072
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280 (11):969-974. https://doi.org/10.1001/jama.280.11.969
doi: 10.1001/jama.280.11.969
pubmed: 9749478
Reese AC, Pierorazio PM, Han M, Partin AW (2012) Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80 (5):1075-1079. https://doi.org/10.1016/j.urology.2012.07.040
doi: 10.1016/j.urology.2012.07.040
pubmed: 22995570
Zumsteg ZS, Zelefsky MJ (2012) Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 13 (6):e259-269. https://doi.org/10.1016/s1470-2045(12)70084-0
doi: 10.1016/s1470-2045(12)70084-0
pubmed: 22652234
Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (6):1938-1942. https://doi.org/10.1097/01.ju.0000158155.33890.e7
doi: 10.1097/01.ju.0000158155.33890.e7
pubmed: 15879786
pmcid: 2948569
van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT (2014) Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. European Urology 65 (6):1078-1083. https://doi.org/10.1016/j.eururo.2014.01.001
doi: 10.1016/j.eururo.2014.01.001
pubmed: 24444476
Wysock JS, Lepor H (2018) Optimizing patient selection for focal therapy-mapping and ablating the index lesion. Transl Androl Urol 7 (Suppl 4):S519-s525. https://doi.org/10.21037/tau.2018.03.16
doi: 10.21037/tau.2018.03.16
pubmed: 30363486
pmcid: 6178318
Burger IA, Muller J, Donati OF, Ferraro DA, Messerli M, Kranzbuhler B, Ter Voert E, Muehlematter UJ, Rupp NJ, Mortezavi A, Eberli D (2019) (68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. J Nucl Med 60 (8):1118-1123. https://doi.org/10.2967/jnumed.118.221564
doi: 10.2967/jnumed.118.221564
pubmed: 30683764
Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76 (3):340-351. https://doi.org/10.1016/j.eururo.2019.02.033
doi: 10.1016/j.eururo.2019.02.033
pubmed: 30898406
Pompe RS, Kühn-Thomä B, Nagaraj Y, Veleva V, Preisser F, Leyh-Bannurah S-R, Graefen M, Huland H, Tilki D, Salomon G (2018) Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI. World Journal of Urology 36 (5):705-712. https://doi.org/10.1007/s00345-018-2238-2
doi: 10.1007/s00345-018-2238-2
pubmed: 29492583
Vargas HA, Wassberg C, Akin O, Hricak H (2012) MR Imaging of Treated Prostate Cancer. Radiology 262 (1):26-42. https://doi.org/10.1148/radiol.11101996
doi: 10.1148/radiol.11101996
pubmed: 22190655
pmcid: 6940010
Donati OF, Jung SI, Vargas HA, Gultekin DH, Zheng J, Moskowitz CS, Hricak H, Zelefsky MJ, Akin O (2013) Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268 (2):440-450. https://doi.org/10.1148/radiol.13122149
doi: 10.1148/radiol.13122149
pubmed: 23481164
pmcid: 6940013
Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190 (5):1180-1186. https://doi.org/10.2214/ajr.07.2924
doi: 10.2214/ajr.07.2924
pubmed: 18430829
Luzurier A, Jouve De Guibert PH, Allera A, Feldman SF, Conort P, Simon JM, Mozer P, Comperat E, Boudghene F, Servois V, Lucidarme O, Granger B, Renard-Penna R (2018) Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. J Magn Reson Imaging 48 (4):1012-1023. https://doi.org/10.1002/jmri.25991
doi: 10.1002/jmri.25991
pubmed: 29517822
Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mege-Lechevallier F, Rabilloud M, Chapelon JY, Lyonnet D (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20 (1):48-55. https://doi.org/10.1007/s00330-009-1520-5
doi: 10.1007/s00330-009-1520-5
pubmed: 19690866
Muller BG, van den Bos W, Brausi M, Futterer JJ, Ghai S, Pinto PA, Popeneciu IV, de Reijke TM, Robertson C, de la Rosette JJ, Scionti S, Turkbey B, Wijkstra H, Ukimura O, Polascik TJ (2015) Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol 33 (10):1503-1509. https://doi.org/10.1007/s00345-014-1475-2
doi: 10.1007/s00345-014-1475-2
pubmed: 25559111
pmcid: 7721864
Rosenkrantz AB, Hindman N, Lim RP, Das K, Babb JS, Mussi TC, Taneja SS (2013) Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. Journal of Magnetic Resonance Imaging 38 (3):694-700. https://doi.org/10.1002/jmri.24016
doi: 10.1002/jmri.24016
pubmed: 23371846
Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A (2001) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40 (3):265-274. https://doi.org/10.1159/000049786
doi: 10.1159/000049786
pubmed: 11684842
Hung S-W, Lin Y-T, Liu M-C (2018) Multiparametric magnetic resonance imaging of prostate cancer. Urological Science 29 (6):266-276. https://doi.org/10.4103/uros.Uros_57_18
doi: 10.4103/uros.Uros_57_18
Dickinson L, Arya M, Afzal N, Cathcart P, Charman SC, Cornaby A, Hindley RG, Lewi H, McCartan N, Moore CM, Nathan S, Ogden C, Persad R, van der Meulen J, Weir S, Emberton M, Ahmed HU (2016) Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. Eur Urol 70 (4):668-674. https://doi.org/10.1016/j.eururo.2016.02.054
doi: 10.1016/j.eururo.2016.02.054
pubmed: 26951947
Mortezavi A, Krauter J, Gu A, Sonderer J, Bruhin J, Reeve KA, Held L, Donati OF, Rupp NJ, Moch H, Sulser T, Eberli D (2019) Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. J Urol 202 (4):717-724. https://doi.org/10.1097/ju.0000000000000298
doi: 10.1097/ju.0000000000000298
pubmed: 31042109
Bass R, Fleshner N, Finelli A, Barkin J, Zhang L, Klotz L (2019) Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol 201 (1):113-119. https://doi.org/10.1016/j.juro.2018.07.040
doi: 10.1016/j.juro.2018.07.040
pubmed: 30577402
Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M (2000) A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163 (1):152-157
doi: 10.1016/S0022-5347(05)67993-1
De Visschere PJ, Naesens L, Libbrecht L, Van Praet C, Lumen N, Fonteyne V, Pattyn E, Villeirs G (2016) What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging? Eur Radiol 26 (4):1098-1107. https://doi.org/10.1007/s00330-015-3894-x
doi: 10.1007/s00330-015-3894-x
pubmed: 26135002
Barret E, Harvey-Bryan KA, Sanchez-Salas R, Rozet F, Galiano M, Cathelineau X (2014) How to diagnose and treat focal therapy failure and recurrence? Curr Opin Urol 24 (3):241-246. https://doi.org/10.1097/mou.0000000000000052
doi: 10.1097/mou.0000000000000052
pubmed: 24625430
Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, Guillaumier S, Hindley RG, Hosking-Jervis F, Leemann L, Lewi H, McCartan N, Moore CM, Nigam R, Odgen C, Persad R, Thalmann GN, Virdi J, Winkler M, Ahmed HU (2020) PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol:101097ju0000000000000747. https://doi.org/10.1097/ju.0000000000000747
Berman RM, Brown AM, Chang SD, Sankineni S, Kadakia M, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2016) DCE MRI of prostate cancer. Abdominal Radiology 41 (5):844-853. https://doi.org/10.1007/s00261-015-0589-3
doi: 10.1007/s00261-015-0589-3
pubmed: 27193787
Gaur S, Turkbey B (2018) Prostate MR Imaging for Posttreatment Evaluation and Recurrence. Radiol Clin North Am 56 (2):263-275. https://doi.org/10.1016/j.rcl.2017.10.008
doi: 10.1016/j.rcl.2017.10.008
pubmed: 29420981
Felker ER, Raman SS, Lu DSK, et al. (2019) Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. American Journal of Roentgenology 213(6):1253–1258. https://doi.org/10.2214/AJR.19.21637
doi: 10.2214/AJR.19.21637
pubmed: 31361529
McCammack KC, Raman SS, Margolis DJ (2016) Imaging of local recurrence in prostate cancer. Future Oncology 12 (21):2401-2415. https://doi.org/10.2217/fon-2016-0122
doi: 10.2217/fon-2016-0122
pubmed: 27306275
Kim CK, Park BK, Park W, Kim SS (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35 (2):246-252. https://doi.org/10.1007/s00261-008-9495-2
doi: 10.1007/s00261-008-9495-2
pubmed: 19130116
Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231 (2):379-385. https://doi.org/10.1148/radiol.2312030011
doi: 10.1148/radiol.2312030011
pubmed: 15064390
Kongnyuy M, Halpern DM, Kosinski KE, Katz AE (2017) Cryosurgery, an alternative treatment option for organ-confined prostate cancer: current beliefs and practice patterns of urologists. Int Urol Nephrol 49 (1):43-48. https://doi.org/10.1007/s11255-016-1440-7
doi: 10.1007/s11255-016-1440-7
pubmed: 27761695
Dickinson L, Ahmed HU, Hindley RG, McCartan N, Freeman A, Allen C, Emberton M, Kirkham AP (2017) Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol 35 (1):30.e39-30.e15. https://doi.org/10.1016/j.urolonc.2016.07.015
Schmid FA, Schindele D, Mortezavi A, Spitznagel T, Sulser T, Schostak M, Eberli D (2020) Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications. Urologic Oncology: Seminars and Original Investigations 38 (4):225-230. https://doi.org/10.1016/j.urolonc.2019.09.001
doi: 10.1016/j.urolonc.2019.09.001
pubmed: 31628038
Rischmann P, Gelet A, Riche B, Villers A, Pasticier G, Bondil P, Jung J-L, Bugel H, Petit J, Toledano H, Mallick S, Rouvière O, Rabilloud M, Tonoli-Catez H, Crouzet S (2017) Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. European Urology 71 (2):267-273. https://doi.org/10.1016/j.eururo.2016.09.039
doi: 10.1016/j.eururo.2016.09.039
pubmed: 27720531
Feijoo ERC, Sivaraman A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Prapotnich D, Cathala N, Mombet A, Cathelineau X (2016) Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. European Urology 69 (2):214-220. https://doi.org/10.1016/j.eururo.2015.06.018
doi: 10.1016/j.eururo.2015.06.018
pubmed: 26164416
Maestroni U, Dinale F, Minari R, Salsi P, Ziglioli F (2012) High-Intensity Focused Ultrasound for Prostate Cancer: Long-Term Followup and Complications Rate. Advances in Urology 2012:960835. https://doi.org/10.1155/2012/960835
doi: 10.1155/2012/960835
pubmed: 22927842
pmcid: 3426178
Fiaschetti V, Manenti G, Di Poce I, Fornari M, Ricci A, Finazzi Agro E, Simonetti G (2012) A Rectourethral Fistula due to Transrectal High-Intensity Focused Ultrasound Treatment: Diagnosis and Management. Case Rep Radiol 2012:962090. https://doi.org/10.1155/2012/962090
doi: 10.1155/2012/962090
pubmed: 23304612
pmcid: 3523592
Tonolini M, Bianco R (2012) Multidetector CT cystography for imaging colovesical fistulas and iatrogenic bladder leaks. Insights into Imaging 3 (2):181-187. https://doi.org/10.1007/s13244-011-0145-9
doi: 10.1007/s13244-011-0145-9
pubmed: 22696044
pmcid: 3314733
Ravichandran S, Ahmed HU, Matanhelia SS, Dobson M (2008) Is There a Role for Magnetic Resonance Imaging in Diagnosing Colovesical Fistulas? Urology 72 (4):832-837. https://doi.org/10.1016/j.urology.2008.06.036
doi: 10.1016/j.urology.2008.06.036
pubmed: 18718640
Bloom JB, Gold SA, Hale GR, Rayn KN, Sabarwal VK, Bakhutashvili I, Valera V, Turkbey B, Pinto PA, Wood BJ (2018) “Super-active surveillance”: MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surgery 7 (2):166-187
doi: 10.21037/gs.2018.03.06
Thüroff S, Chaussy G, Kiel H (2003) Transrectal focused ultrasound (HIFU) in prostate cancer. European Urology Supplements 2 (1):135. https://doi.org/10.1016/S1569-9056(03)80533-X
doi: 10.1016/S1569-9056(03)80533-X
Netsch C, Bach T, Gross E, Gross AJ (2011) Rectourethral fistula after high-intensity focused ultrasound therapy for prostate cancer and its surgical management. Urology 77 (4):999-1004. https://doi.org/10.1016/j.urology.2010.10.028
doi: 10.1016/j.urology.2010.10.028
pubmed: 21215427
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology 17 (6):1471-1474. https://doi.org/10.1245/s10434-010-0985-4
Boutier R, Girouin N, Cheikh AB, Belot A, Rabilloud M, Gelet A, Chapelon J-Y, Rouvière O (2011) Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer. BJU International 108 (11):1776-1781. https://doi.org/10.1111/j.1464-410X.2011.10251.x
doi: 10.1111/j.1464-410X.2011.10251.x
pubmed: 21711432
Anttinen M, Mäkelä P, Suomi V, Kiviniemi A, Saunavaara J, Sainio T, Horte A, Eklund L, Taimen P, Sequeiros RB, Boström PJ (2019) Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scandinavian Journal of Urology 53 (5):295-302. https://doi.org/10.1080/21681805.2019.1660707
doi: 10.1080/21681805.2019.1660707
pubmed: 31556779
Yap T, Ahmed HU, Hindley RG, Guillaumier S, McCartan N, Dickinson L, Emberton M, Minhas S (2016) The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. European Urology 69 (5):844-851. https://doi.org/10.1016/j.eururo.2015.10.030
doi: 10.1016/j.eururo.2015.10.030
pubmed: 26525837
Shoji S, Nakano M, Fujikawa H, Endo K, Hashimoto A, Tomonaga T, Terachi T, Uchida T (2015) Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes. International Journal of Urology 22 (11):1043-1049 https://doi.org/10.1111/iju.12876
doi: 10.1111/iju.12876
pubmed: 26251127